(CRBN) Corbion - Ratings and Ratios
Lactic, Acid, Derivatives, Emulsifiers, Bioplastics
Description: CRBN Corbion
Corbion NV, a Dutch specialty chemicals company, operates in a sector driven by demand for sustainable and innovative solutions. The companys quarterly income tax expense is a critical component of its financial performance, influencing its net income and profitability.
To evaluate Corbion NVs stock (CRBN), its essential to consider key performance indicators (KPIs) such as revenue growth, gross margin, and return on equity (RoE). The companys RoE of 15.94% indicates a relatively strong ability to generate profits from shareholders equity. Additionally, the forward price-to-earnings (P/E) ratio of 12.89 suggests that the stock may be undervalued, as it implies a lower expected earnings multiple compared to its current P/E of 14.74.
The specialty chemicals industry is influenced by various economic drivers, including global demand for food preservation, pharmaceuticals, and bioplastics. Corbion NVs market capitalization of 962.10M EUR indicates a moderate size, potentially allowing for agile decision-making while still maintaining a significant market presence. The stocks beta of 1.015 suggests that its price movements are closely correlated with the overall market, implying a relatively average level of systematic risk.
To further analyze CRBN, its crucial to examine the companys quarterly earnings reports, focusing on metrics such as sales growth, operating expenses, and tax rates. By deconstructing these components, investors can gain a deeper understanding of Corbion NVs financial health and identify potential areas for improvement. Moreover, monitoring industry trends, competitor activity, and macroeconomic factors will help investors make informed decisions about the stocks future prospects.
CRBN Stock Overview
| Market Cap in USD | 1,177m |
| Sub-Industry | Specialty Chemicals |
| IPO / Inception |
CRBN Stock Ratings
| Growth Rating | -69.3% |
| Fundamental | 76.5% |
| Dividend Rating | 51.0% |
| Return 12m vs S&P 500 | -32.9% |
| Analyst Rating | - |
CRBN Dividends
| Dividend Yield 12m | 3.40% |
| Yield on Cost 5y | 1.85% |
| Annual Growth 5y | 4.86% |
| Payout Consistency | 92.3% |
| Payout Ratio | 57.1% |
CRBN Growth Ratios
| Growth Correlation 3m | -88.2% |
| Growth Correlation 12m | -88.9% |
| Growth Correlation 5y | -86% |
| CAGR 5y | -12.79% |
| CAGR/Max DD 5y | -0.19 |
| Sharpe Ratio 12m | -0.16 |
| Alpha | -33.48 |
| Beta | 0.397 |
| Volatility | 28.47% |
| Current Volume | 64.6k |
| Average Volume 20d | 95.7k |
| Stop Loss | 16.7 (-3.1%) |
| Signal | -0.97 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (111.1m TTM) > 0 and > 6% of Revenue (6% = 132.9m TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA 5.24pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 3.39% (prev 1.67%; Δ 1.72pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.15 (>3.0%) and CFO 226.3m > Net Income 111.1m (YES >=105%, WARN >=100%) |
| Net Debt (400.9m) to EBITDA (328.9m) ratio: 1.22 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.17 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (58.1m) change vs 12m ago NaN% (target <= -2.0% for YES) |
| Gross Margin 23.54% (prev 22.70%; Δ 0.84pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 136.4% (prev 73.11%; Δ 63.33pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 4.47 (EBITDA TTM 328.9m / Interest Expense TTM 45.7m) >= 6 (WARN >= 3) |
Altman Z'' 3.51
| (A) 0.05 = (Total Current Assets 513.0m - Total Current Liabilities 438.0m) / Total Assets 1.55b |
| (B) 0.44 = Retained Earnings (Balance) 675.8m / Total Assets 1.55b |
| (C) 0.13 = EBIT TTM 204.2m / Avg Total Assets 1.62b |
| (D) 0.87 = Book Value of Equity 675.8m / Total Liabilities 773.8m |
| Total Rating: 3.51 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 76.47
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 7.08% = 3.54 |
| 3. FCF Margin 4.51% = 1.13 |
| 4. Debt/Equity 0.58 = 2.33 |
| 5. Debt/Ebitda 1.37 = 1.19 |
| 6. ROIC - WACC 8.79% = 10.99 |
| 7. RoE 15.94% = 1.33 |
| 8. Rev. Trend 71.19% = 3.56 |
| 9. Rev. CAGR 13.83% = 1.73 |
| 10. EPS Trend 7.12% = 0.18 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of CRBN shares?
Over the past week, the price has changed by -1.77%, over one month by -3.26%, over three months by -8.79% and over the past year by -21.54%.
Is Corbion a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CRBN is around 14.32 EUR . This means that CRBN is currently overvalued and has a potential downside of -16.89%.
Is CRBN a buy, sell or hold?
What are the forecasts/targets for the CRBN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 22.7 | 31.9% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 15.7 | -8.9% |
CRBN Fundamental Data Overview
Market Cap EUR = 1.01b (1.01b EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 49.3m EUR (Cash only, last quarter)
P/E Trailing = 15.5856
P/E Forward = 13.624
P/S = 0.7792
P/B = 1.3849
Beta = 1.015
Revenue TTM = 2.21b EUR
EBIT TTM = 204.2m EUR
EBITDA TTM = 328.9m EUR
Long Term Debt = 262.2m EUR (from longTermDebt, last quarter)
Short Term Debt = 188.0m EUR (from shortLongTermDebt, last quarter)
Debt = 450.2m EUR (Calculated: Short Term 188.0m + Long Term 262.2m)
Net Debt = 400.9m EUR (from netDebt column, last quarter)
Enterprise Value = 1.41b EUR (1.01b + Debt 450.2m - CCE 49.3m)
Interest Coverage Ratio = 4.47 (Ebit TTM 204.2m / Interest Expense TTM 45.7m)
FCF Yield = 7.08% (FCF TTM 99.9m / Enterprise Value 1.41b)
FCF Margin = 4.51% (FCF TTM 99.9m / Revenue TTM 2.21b)
Net Margin = 5.02% (Net Income TTM 111.1m / Revenue TTM 2.21b)
Gross Margin = 23.54% ((Revenue TTM 2.21b - Cost of Revenue TTM 1.69b) / Revenue TTM)
Tobins Q-Ratio = 2.09 (Enterprise Value 1.41b / Book Value Of Equity 675.8m)
Interest Expense / Debt = 4.86% (Interest Expense 21.9m / Debt 450.2m)
Taxrate = 2.64% (from quarterly Income Tax Expense: 1.20m / 45.4m)
NOPAT = 198.9m (EBIT 204.2m * (1 - 2.64%))
Current Ratio = 1.17 (Total Current Assets 513.0m / Total Current Liabilities 438.0m)
Debt / Equity = 0.58 (Debt 450.2m / last Quarter total Stockholder Equity 772.5m)
Debt / EBITDA = 1.37 (Net Debt 400.9m / EBITDA 328.9m)
Debt / FCF = 4.51 (Debt 450.2m / FCF TTM 99.9m)
Total Stockholder Equity = 696.9m (last 4 quarters mean)
RoA = 7.18% (Net Income 111.1m, Total Assets 1.55b )
RoE = 15.94% (Net Income TTM 111.1m / Total Stockholder Equity 696.9m)
RoCE = 21.30% (Ebit 204.2m / (Equity 696.9m + L.T.Debt 262.2m))
RoIC = 15.42% (NOPAT 198.9m / Invested Capital 1.29b)
WACC = 6.63% (E(1.01b)/V(1.46b) * Re(7.48%)) + (D(450.2m)/V(1.46b) * Rd(4.86%) * (1-Tc(0.03)))
Shares Correlation 5-Years: 20.0 | Cagr: 0.35%
Discount Rate = 7.48% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈68.2m ; Y1≈44.8m ; Y5≈20.5m
Fair Price DCF = 6.93 (DCF Value 402.6m / Shares Outstanding 58.1m; 5y FCF grow -40.0% → 3.0% )
Revenue Correlation: 71.19 | Revenue CAGR: 13.83%
Rev Growth-of-Growth: -3.84
EPS Correlation: 7.12 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 276.0